OrganiGram Holdings Inc represents a commitment to excellence, sustainability, and innovation in the cannabis industry. With a focus on producing high-quality, organic cannabis products, OrganiGram prioritizes the well-being of its customers and the environment. The company's corporate philosophy is centered around providing safe and reliable cannabis options, while also valuing social responsibility and community engagement. OrganiGram is dedicated to cultivating relationships with its customers, understanding their needs, and consistently delivering superior products. By upholding these core values, OrganiGram Holdings Inc strives to be a trusted leader in the cannabis market.

OrganiGram Holdings Inc is primarily present in Canada.

OrganiGram Holdings Inc has achieved several significant milestones in its operations. Firstly, the company expanded its production capacity through the completion of Phase 3 expansion in 2019. This expansion enabled OrganiGram to increase its annual cannabis production capacity to 76,000 kilograms. Additionally, OrganiGram has successfully developed innovative cannabis derivative products, such as cannabis-infused chocolates and powdered beverages. Moreover, the company has received various certifications, including organic certification by Pro-Cert, which further demonstrates its commitment to producing high-quality and sustainable cannabis products. By focusing on expansion, innovation, and quality, OrganiGram Holdings Inc has established itself as a leading player in the cannabis industry.

OrganiGram Holdings Inc is a Canadian cannabis company that was founded in 2013. It is a licensed producer of medical marijuana, with cultivation facilities located in Moncton, New Brunswick. The company's mission is to provide high-quality, organically-grown cannabis products to both medical and adult-use recreational consumers. OrganiGram Holdings Inc has a strong focus on innovation and sustainability, employing advanced growing techniques and operating under strict quality control measures. With a diverse product line and a commitment to customer satisfaction, OrganiGram Holdings Inc has established itself as a leading player in the cannabis industry.

The main competitors of OrganiGram Holdings Inc in the market include companies such as Canopy Growth Corporation and Aurora Cannabis Inc.

OrganiGram Holdings Inc is primarily active in the cannabis industry.

The business model of OrganiGram Holdings Inc is focused on the cultivation, production, and distribution of high-quality cannabis products. As a leading Canadian licensed producer, OrganiGram operates state-of-the-art indoor facilities to ensure consistent, premium cannabis cultivation. The company's business model revolves around their commitment to innovation, sustainability, and customer satisfaction. By leveraging advanced growing techniques, strategic partnerships, and a diverse product portfolio, OrganiGram aims to cater to both medical and adult-use recreational cannabis markets. With a customer-centric approach and ongoing research and development, OrganiGram Holdings Inc strives to deliver safe, reliable, and exceptional cannabis experiences while contributing to the overall growth of the industry.

OrganiGram Holdings KGV ir -4,12.

OrganiGram Holdings KUV ir 1,18.

AlleAktien kvalitātes vērtējums OrganiGram Holdings ir 5/10.

gaidāmā OrganiGram Holdings apgrozījums ir 162,28 milj. CAD.

gaidāmā OrganiGram Holdings peļņa ir -46,52 milj. CAD.

OrganiGram Holdings Inc. is a Canadian company specializing in the production, distribution, and marketing of medical cannabis. The business model of OrganiGram includes a wide range of products that can be used for a variety of medical conditions and symptoms. OrganiGram's main focus is the production of cannabis flowers rich in cannabinoids such as THC and CBD. These flowers are offered in different formats, including dried, pressed buds and cured flowers that can be used in capsules or vaporizers. OrganiGram also offers various strains of cannabis flowers specifically developed for different medical conditions or symptoms. In addition to cannabis flowers, OrganiGram also produces various other cannabis products, such as oils and extracts. These products are made from the flowers of the cannabis plant and provide a convenient way to harness the health benefits of cannabis without actually having to smoke or vaporize it. OrganiGram also offers vaporizable oils specifically developed for medical purposes. Another product segment of OrganiGram includes edible products made from cannabis. These include chocolates, candies, and beverages, all of which contain a controlled amount of cannabinoids and are specially developed for medical purposes. OrganiGram also offers a variety of accessories and other products specifically designed for the use of medical cannabis, including vaporizers, capsules, rolling papers, and other utensils suitable for use with OrganiGram's cannabis products. To produce and distribute these products, OrganiGram has developed a comprehensive cultivation system that ensures the flowers and plants are of the highest quality. The company utilizes state-of-the-art technology and methods to ensure the purity, efficacy, and quality of its products. In addition, OrganiGram operates a wide range of online and retail activities to market and sell its products. The company uses a variety of traditional and digital marketing channels to raise awareness of its brand and promote awareness of the health benefits of medical cannabis. Overall, OrganiGram's business model is very diverse and includes a variety of products and services specifically tailored to the use of medical cannabis. Through its innovative research and development, advanced cultivation system, and comprehensive marketing strategy, OrganiGram is able to serve a growing customer base seeking safe and effective products for symptom relief and disease management.

OrganiGram Holdings izmaksā dividendes 0 CAD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt OrganiGram Holdings vai uzņēmums nedod dividendes.

OrganiGram Holdings ISIN ir CA68620P1018.

OrganiGram Holdings simbols ir OGI.TO.

Pēdējo 12 mēnešu laikā OrganiGram Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos OrganiGram Holdings plāno maksāt dividendes 0 CAD apmērā.

OrganiGram Holdings pašreizējā dividendu rentabilitāte ir .

OrganiGram Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

OrganiGram Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 CAD. Tas atbilst dividendes ražībai 0 %.

OrganiGram Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu OrganiGram Holdings apmērā 0 CAD, kas tika izmaksāta 3.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 3.10.2024..

Pēdējās dividendes izmaksa notika 3.10.2024..

Gadā 2023, OrganiGram Holdings izmaksāja 0 CAD dividendes.

OrganiGram Holdings dividendes tiek izmaksātas CAD.